Journal of Clinical Oncology, Vol 18, Issue 13
(July), 2000: 2560-2566
© 2000 American Society for Clinical Oncology
Sentinel Lymph Node Biopsy for Breast Cancer: A Suitable Alternative to Routine Axillary Dissection in Multi-Institutional Practice When Optimal Technique Is Used
By Kelly M. McMasters,
Todd M. Tuttle,
David J. Carlson,
C. Matthew Brown,
R. Dirk Noyes,
Rebecca L. Glaser,
Donald J. Vennekotter,
Peter S. Turk,
Peter S. Tate,
Armando Sardi,
Patricia B. Cerrito,
Michael J. Edwards
From the Department of Surgery, Division of Surgical Oncology, J. Graham Brown Cancer Center, and Department of Mathematics, University of Louisville, Louisville, KY; Park Nicollett Clinic, Minneapolis, MN; St. Mary’s Medical Center and Deaconess Hospital, Evansville, IN; Norton Hospital, Louisville, and Central Baptist Hospital, Lexington, KY; LDS Hospital, Salt Lake City, UT; Franciscan Medical Center, Dayton, and Kettering Memorial Hospital, Kettering, OH; Presbyterian Hospital, Charlotte, NC; and St. Agnes Healthcare, Baltimore, MD.
Address reprint requests to Kelly M. McMasters, MD, PhD, University of Louisville-Brown Cancer Center, 529 S Jackson St, Louisville, KY 40202; email kelly.mcmasters{at}nortonhealthcare.org
PURPOSE: Previous studies have demonstrated the feasibility of sentinel lymph node (SLN) biopsy for nodal staging of patients with breast cancer. However, unacceptably high false-negative rates have been reported in several studies, raising doubt about the applicability of this technique in widespread surgical practice. Controversy persists regarding the optimal technique for correctly identifying the SLN. Some investigators advocate SLN biopsy using injection of a vital blue dye, others recommend radioactive colloid, and still others recommend the use of both agents together.
PATIENTS AND METHODS: A total of 806 patients were enrolled by 99 surgeons. SLN biopsy was performed by single-agent (blue dye alone or radioactive colloid alone) or dual-agent injection at the discretion of the operating surgeon. All patients underwent attempted SLN biopsy followed by completion level I/II axillary lymph node dissection to determine the false-negative rate.
RESULTS: There was no significant difference (86% v 90%) in the SLN identification rate among patients who underwent single- versus dual-agent injection. The false-negative rates were 11.8% and 5.8% for single- versus dual-agent injection, respectively (P < .05). Dual-agent injection resulted in a greater mean number of SLNs identified per patient (2.1 v 1.5; P < .0001). The SLN identification rate was significantly less for patients older than 50 years as compared with that of younger patients (87.6% v 92.6%; P = .03). Upper-outer quadrant tumor location was associated with an increased likelihood of a false-negative result compared with all other locations (11.2% v 3.9%; P < .05).
CONCLUSION: In multi-institutional practice, SLN biopsy using dual-agent injection provides optimal sensitivity for detection of nodal metastases. The acceptable SLN identification and false-negative rates associated with the dual-agent injection technique indicate that this procedure is a suitable alternative to routine axillary dissection across a wide spectrum of surgical practice and hospital environments.
 CiteULike  Complore  Connotea  Del.icio.us  Digg  Facebook  Reddit  Technorati  Twitter What's this?
This article has been cited by other articles:
|
|
|
|
 
A. Chung, J. Yu, M. Stempel, S. Patil, H. Cody III, and L. Montgomery
Is the "10% Rule" Equally Valid for All Subsets of Sentinel-Node-Positive Breast Cancer Patients?
Ann. Surg. Oncol.,
October 1, 2008;
15(10):
2728 - 2733.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
K. A. Vanderveen, R. Ramsamooj, and R. J. Bold
A Prospective, Blinded Trial of Touch Prep Analysis versus Frozen Section for Intraoperative Evaluation of Sentinel Lymph Nodes in Breast Cancer
Ann. Surg. Oncol.,
July 1, 2008;
15(7):
2006 - 2011.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
E. M. Sevick-Muraca, R. Sharma, J. C. Rasmussen, M. V. Marshall, J. A. Wendt, H. Q. Pham, E. Bonefas, J. P. Houston, L. Sampath, K. E. Adams, et al.
Imaging of Lymph Flow in Breast Cancer Patients after Microdose Administration of a Near-Infrared Fluorophore: Feasibility Study
Radiology,
March 1, 2008;
246(3):
734 - 741.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
K. D. Evans, X. Li, S. R. Robertson, A. M. Boyd, and M. Knopp
Sonographic Assessment of Axillary Lymph Nodes After a Mammographically Recommended Breast Sonogram for Women 55 Years and Older: A Feasibility Study
Journal of Diagnostic Medical Sonography,
September 1, 2007;
23(5):
263 - 271.
[Abstract]
[PDF]
|
|
|
|
|
|
|
K. A. Vanderveen, D. A. Paterniti, R. L. Kravitz, and R. J. Bold
Diffusion of Surgical Techniques in Early Stage Breast Cancer: Variables Related to Adoption and Implementation of Sentinel Lymph Node Biopsy
Ann. Surg. Oncol.,
May 1, 2007;
14(5):
1662 - 1669.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. M. Mondi, R. E. Cuenca, D. W. Ollila, J. H. Stewart IV, and E. A. Levine
Sentinel Lymph Node Biopsy During Pregnancy: Initial Clinical Experience
Ann. Surg. Oncol.,
January 1, 2007;
14(1):
218 - 221.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. L. Chen, D. M. Iddings, R. P. Scheri, and A. J. Bilchik
Lymphatic Mapping and Sentinel Node Analysis: Current Concepts and Applications
CA Cancer J Clin,
September 1, 2006;
56(5):
292 - 309.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. Knauer, P. Konstantiniuk, A. Haid, E. Wenzl, M. Riegler-Keil, S. Postlberger, R. Reitsamer, and P. Schrenk
Multicentric Breast Cancer: A New Indication for Sentinel Node Biopsy--A Multi-Institutional Validation Study
J. Clin. Oncol.,
July 20, 2006;
24(21):
3374 - 3380.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
I. Sachelarie, M. L. Grossbard, M. Chadha, S. Feldman, M. Ghesani, and R. H. Blum
Primary Systemic Therapy of Breast Cancer
Oncologist,
June 1, 2006;
11(6):
574 - 589.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
C. Tsopelas, E. Bevington, J. Kollias, S. Shibli, G. Farshid, B. Coventry, and B. E. Chatterton
99mTc-Evans Blue Dye for Mapping Contiguous Lymph Node Sequences and Discriminating the Sentinel Lymph Node in an Ovine Model
Ann. Surg. Oncol.,
May 1, 2006;
13(5):
692 - 700.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
H. C. Snider Jr., E. Rubin, and R. Henson
Axillary Ultrasonography to Detect Recurrence After Sentinel Node Biopsy in Breast Cancer
Ann. Surg. Oncol.,
April 1, 2006;
13(4):
501 - 507.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
G. H. Lyman, A. E. Giuliano, M. R. Somerfield, A. B. Benson III, D. C. Bodurka, H. J. Burstein, A. J. Cochran, H. S. Cody III, S. B. Edge, S. Galper, et al.
American Society of Clinical Oncology Guideline Recommendations for Sentinel Lymph Node Biopsy in Early-Stage Breast Cancer
J. Clin. Oncol.,
October 20, 2005;
23(30):
7703 - 7720.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. U. Buzdar, K. K. Hunt, D. Berry, and G. N. Hortobagyi
In Reply:
J. Clin. Oncol.,
September 20, 2005;
23(27):
6804 - 6805.
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. C. Degnim, K. Oh, V. M. Cimmino, K. M. Diehl, A. E. Chang, L. A. Newman, and M. S. Sabel
Is Blue Dye Indicated for Sentinel Lymph Node Biopsy in Breast Cancer Patients With a Positive Lymphoscintigram?
Ann. Surg. Oncol.,
September 1, 2005;
12(9):
712 - 717.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
E. P. Mamounas, A. Brown, S. Anderson, R. Smith, T. Julian, B. Miller, H. D. Bear, C. B. Caldwell, A. P. Walker, W. M. Mikkelson, et al.
Sentinel Node Biopsy After Neoadjuvant Chemotherapy in Breast Cancer: Results From National Surgical Adjuvant Breast and Bowel Project Protocol B-27
J. Clin. Oncol.,
April 20, 2005;
23(12):
2694 - 2702.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J.S. Rietman, P.U. Dijkstra, J.H. B. Geertzen, P. Baas, J. de Vries, W.V. Dolsma, J.W. Groothoff, W.H. Eisma, and H.J. Hoekstra
Treatment-Related Upper Limb Morbidity 1 Year after Sentinel Lymph Node Biopsy or Axillary Lymph Node Dissection for Stage I or II Breast Cancer
Ann. Surg. Oncol.,
November 1, 2004;
11(11):
1018 - 1024.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
E. P. Mamounas
Tailoring Loco-Regional Therapy with Neoadjuvant Chemotherapy: Another Step in the Right Direction
Ann. Surg. Oncol.,
October 1, 2004;
11(10):
888 - 891.
[Full Text]
[PDF]
|
|
|
|
|
|
|
N Lamichhane, K W Shen, C L Li, Q X Han, Y J Zhang, Z M Shao, and Z Z Shen
Sentinel lymph node biopsy in breast cancer patients after overnight migration of radiolabelled sulphur colloid
Postgrad. Med. J.,
September 1, 2004;
80(947):
546 - 550.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. J. Ellner, J. Mendez, D. R. Vera, C. K. Hoh, W. L. Ashburn, and A. M. Wallace
Sentinel Lymph Node Mapping of the Colon and Stomach Using Lymphoseek in a Pig Model
Ann. Surg. Oncol.,
July 1, 2004;
11(7):
674 - 681.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
T. A. King, J. V. Fey, K. J. Van Zee, A. S. Heerdt, M. L. Gemignani, E. R. Port, L. Sclafani, V. Sacchini, J. A. Petrek, H. S. Cody III, et al.
A Prospective Analysis of the Effect of Blue-Dye Volume on Sentinel Lymph Node Mapping Success and Incidence of Allergic Reaction in Patients With Breast Cancer
Ann. Surg. Oncol.,
May 1, 2004;
11(5):
535 - 541.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
B. R. Krynyckyi, C. K. Kim, M. R. Goyenechea, P. T. Chan, Z.-Y. Zhang, and J. Machac
Clinical Breast Lymphoscintigraphy: Optimal Techniques for Performing Studies, Image Atlas, and Analysis of Images
RadioGraphics,
January 1, 2004;
24(1):
121 - 145.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
F.C. Wright, J. Walker, C.H.L. Law, and D.R. McCready
Outcomes After Localized Axillary Node Recurrence in Breast Cancer
Ann. Surg. Oncol.,
November 1, 2003;
10(9):
1054 - 1058.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
C. T. Kuo, D. S.B. Hoon, H. Takeuchi, R. Turner, H.-J. Wang, D. L. Morton, and B. Taback
Prediction of Disease Outcome in Melanoma Patients by Molecular Analysis of Paraffin-Embedded Sentinel Lymph Nodes
J. Clin. Oncol.,
October 1, 2003;
21(19):
3566 - 3572.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
E. P. Mamounas
NSABP Breast Cancer Clinical Trials: Recent Results and Future Directions
Clin. Med. Res.,
October 1, 2003;
1(4):
309 - 326.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
B. R. Krynyckyi, H. Chun, H. H. Kim, Y. Eskandar, C. K. Kim, and J. Machac
Factors Affecting Visualization Rates of Internal Mammary Sentinel Nodes During Lymphoscintigraphy
J. Nucl. Med.,
September 1, 2003;
44(9):
1387 - 1393.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
C. Nos, P. Freneaux, C. Louis-Sylvestre, J. S. Hurren, D. Heitz, X. Sastre-Garau, and K. B. Clough
Macroscopic Quality Control Improves the Reliability of Blue Dye-Only Sentinel Lymph Node Biopsy in Breast Cancer
Ann. Surg. Oncol.,
June 1, 2003;
10(5):
525 - 530.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
B. D. Badgwell, S. P. Povoski, S. F. Abdessalam, D. C. Young, W. B. Farrar, M. J. Walker, L. D. Yee, E. E. Zervos, W. E. Carson III, and W. E. Burak Jr
Patterns of Recurrence After Sentinel Lymph Node Biopsy for Breast Cancer
Ann. Surg. Oncol.,
May 1, 2003;
10(4):
376 - 380.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
D. K. Blanchard, J. H. Donohue, C. Reynolds, and C. S. Grant
Relapse and Morbidity in Patients Undergoing Sentinel Lymph Node Biopsy Alone or With Axillary Dissection for Breast Cancer
Arch Surg,
May 1, 2003;
138(5):
482 - 488.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. Simmons, S. Thevarajah, M. B. Brennan, P. Christos, and M. Osborne
Methylene Blue Dye as an Alternative to Isosulfan Blue Dye for Sentinel Lymph Node Localization
Ann. Surg. Oncol.,
April 1, 2003;
10(3):
242 - 247.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
I. A. Jacobs, C. K. Chang, T. K. DasGupta, and G. Salti
High Isotope Counts and Sentinel Node Positivity in Patients With Melanoma
Arch Surg,
January 1, 2003;
138(1):
63 - 66.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. Koizumi, M. Makita, M. Yoshimoto, F. Kasumi, G. Sakamoto, and E. Ogata
Indications for Sentinel Lymph Node Biopsy in Patients with Breast Cancer: Retrospective and Simulation Analyses
Jpn. J. Clin. Oncol.,
December 1, 2002;
32(12):
517 - 524.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
K. K. Swenson, M. J. Nissen, C. Ceronsky, L. Swenson, M. W. Lee, and T. M. Tuttle
Comparison of Side Effects Between Sentinel Lymph Node and Axillary Lymph Node Dissection for Breast Cancer
Ann. Surg. Oncol.,
October 1, 2002;
9(8):
745 - 753.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
G. Lawrence, J. Crawford, F. Sherman, J. A. van der Hage, and C. J.H. van de Velde
Evaluating Neoadjuvant Chemotherapy in Breast Cancer
J. Clin. Oncol.,
June 15, 2002;
20(12):
2905 - 2907.
[Full Text]
[PDF]
|
|
|
|
|
|
|
D. A. Litvak and A. E. Giuliano
The Results of the Department of Defense's Breast Lymphatic Mapping Study
Ann. Surg. Oncol.,
June 1, 2002;
9(5):
428 - 429.
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. L. Wong, M. J. Edwards, C. Chao, T. M. Tuttle, R. D. Noyes, D. J. Carlson, A. L. Laidley, T. Q. McGlothin, P. B. Ley, C. M. Brown, et al.
The Effect of Prior Breast Biopsy Method and Concurrent Definitive Breast Procedure on Success and Accuracy of Sentinel Lymph Node Biopsy
Ann. Surg. Oncol.,
April 1, 2002;
9(3):
272 - 277.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
K. M. McMasters, S. L. Wong, and C. Chao
Comment on the article "Highest Isotope Count Does Not Predict Sentinel Node Positivity in All Breast Cancer Patients," by Martin et al., August 2001, Annals of Surgical Oncology
Ann. Surg. Oncol.,
April 1, 2002;
9(3):
317 - 318.
[Full Text]
[PDF]
|
|
|
|
|
|
|
P.J. Tanis, O.E. Nieweg, A.A. M. Hart, and B.B. R. Kroon
The Illusion of the Learning Phase for Lymphatic Mapping
Ann. Surg. Oncol.,
March 1, 2002;
9(2):
142 - 147.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
W. Goessling, P. H. McKee, and R. J. Mayer
Merkel Cell Carcinoma
J. Clin. Oncol.,
January 15, 2002;
20(2):
588 - 598.
[Full Text]
[PDF]
|
|
|
|
|
|
|
T. M. Tuttle, M. Colbert, R. Christensen, K. J. Ose, T. Jones, R. Wetherille, J. Friedman, K. Swenson, and K. M. McMasters
Subareolar Injection of 99mTc Facilitates Sentinel Lymph Node Identification
Ann. Surg. Oncol.,
January 1, 2002;
9(1):
77 - 81.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. D. McCarter, H. Yeung, S. Yeh, J. Fey, P. I. Borgen, and H. S. Cody III
Localization of the Sentinel Node in Breast Cancer: Identical Results With Same-Day and Day-Before Isotope Injection
Ann. Surg. Oncol.,
September 1, 2001;
8(8):
682 - 686.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. C.G. Martin, J. Fey, H. Yeung, P. I. Borgen, and H. S. Cody III
Highest Isotope Count Does Not Predict Sentinel Node Positivity in All Breast Cancer Patients
Ann. Surg. Oncol.,
August 1, 2001;
8(7):
592 - 597.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. Cantin, H. Scarth, M. Levine, and M. Hugi
Clinical practice guidelines for the care and treatment of breast cancer: 13. Sentinel lymph node biopsy
Can. Med. Assoc. J.,
July 1, 2001;
165(2):
166 - 173.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. L. Wong, M. J. Edwards, C. Chao, T. M. Tuttle, R. D. Noyes, C. Woo, P. B. Cerrito, K. M. McMasters, and for the University of Louisville Breast Cancer Sen
Predicting the Status of the Nonsentinel Axillary Nodes: A Multicenter Study
Arch Surg,
May 1, 2001;
136(5):
563 - 568.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. J. Rosser, A. Giuliano, and K. McMasters
Safety of Sentinel Lymph Node Dissection and Significance of Cytokeratin Micrometastases
J. Clin. Oncol.,
March 15, 2001;
19(6):
1882 - 1883.
[Full Text]
|
|
|
|
